Does Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) Look Expensive At $11.50? Here’s How To Know.

In last trading session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) saw 0.51 million shares changing hands with its beta currently measuring 1.65. Company’s recent per share price level of $11.50 trading at -$0.04 or -0.35% at ring of the bell on the day assigns it a market valuation of $813.85M. That closing price of ZNTL’s stock is at a discount of -173.57% from its 52-week high price of $31.46 and is indicating a premium of 16.87% from its 52-week low price of $9.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 862.66K if we extend that period to 3-months.

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information

Upright in the red during last session for losing -0.35%, in the last five days ZNTL remained trading in the red while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $11.50 price level, adding 2.95% to its value on the day. Zentalis Pharmaceuticals Inc’s shares saw a change of -24.09% in year-to-date performance and have moved -0.78% in past 5-day. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) showed a performance of -28.04% in past 30-days. Number of shares sold short was 13.07 million shares which calculate 12.75 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts

Statistics highlight that Zentalis Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -56.99% of value to its shares in past 6 months, showing an annual growth rate of -0.22% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -66.20% during past 5 years.

ZNTL Dividends

Zentalis Pharmaceuticals Inc is more likely to be releasing its next quarterly report in March and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

On Key

Related Posts